Previous Close | 968.00 |
Open | 970.00 |
Bid | 972.41 x 100 |
Ask | 973.87 x 100 |
Day's Range | 966.85 - 979.98 |
52 Week Range | 684.81 - 998.33 |
Volume | |
Avg. Volume | 455,508 |
Market Cap | 107.299B |
Beta (5Y Monthly) | 0.17 |
PE Ratio (TTM) | 28.73 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps TARRYTOWN, N.Y. and PARIS, May 13, 2024 (GLOBE NEWSWIRE) -
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing Phase 1/2 CHORD trial is currently enrolling infants and children in the U.S., UK and Spain TARRYTOWN, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) wi
TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Tuesday, May 14, 2024Jefferies Global Healthcare Conference at 8:30 a.m. ET on Wednesday, June 5, 2024Goldman Sachs 45th Annual Global Healthcare Conference at 8:00 a.m. ET on Tuesday, June 11, 2024 The sessions may be accessed from the "Investors & Media" page of Regeneron's website